GLP-1 ad war goes to court as Novo Nordisk accuses Lilly of misleading Wegovy–Zepbound ads
TL;DR Summary
Novo Nordisk filed a lawsuit alleging Eli Lilly’s GLP-1 weight‑loss ads mislead viewers by comparing Wegovy to Zepbound using Wegovy’s lower-dose data from outdated studies while ignoring Wegovy’s own high‑dose results; Lilly says the ads disclose that the high‑dose Wegovy data isn’t included and defends the head‑to‑head trial as the gold standard.
- GLP-1 ad war spills into court as Novo Nordisk alleges Eli Lilly ignores science The Washington Post
- Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising CNBC
- Ozempic maker Novo Nordisk sues US rival over ‘materially misleading’ ads | Pharmaceuticals industry The Guardian
- Novo Nordisk says it’s suing Eli Lilly, accusing it of false advertising NBC News
- Novo Sues Rival Lilly Over Alleged False Advertising in Weight-Loss Ads WSJ
Reading Insights
Total Reads
0
Unique Readers
3
Time Saved
18 min
vs 19 min read
Condensed
99%
3,638 → 52 words
Want the full story? Read the original article
Read on The Washington Post